Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · THYROCARE

THYROCARE

HealthcareHealthcare Services₹8013 cr market cap
₹504.85 ▲ +0.25% today As of 19 Nov 2026
52-week low ₹349.5552-week high ₹649.35

-22.4% from the 52-week high · +44.1% above the low

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 1,645 full-time employees. The company went IPO on 2016-05-09. The firm has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The firm's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The firm has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.

The short version. THYROCARE reported revenue of ₹271 crore for Sep 2026, up 24.9% from a year earlier. Net profit was ₹16 crore (down 66.7% year on year). Return on equity was 27.9% in Mar 2026. Promoter holding was 51.02% in Sep 2026, down 20.04 points over 8 quarters.

1 · The price

How has the stock traded?

THYROCARE trades 22.4% below its 52-week high and 44.1% above its 52-week low.

Change over period: —

1M+6.9%
3M-13.5%
6M+6.0%
1Y-5.1%

2 · The business

Is it growing?

Sales, year on year+24.9%

Sep 2026 revenue of ₹271 cr.

Profit, year on year-66.7%

Sep 2026 net profit of ₹16 cr.

Net margin5.9%

16.3 pts lower than a year earlier.

3-year growth36.2% profit

Revenue compounded at 16.5% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue271240224196217193187166
Net profit1652472948392219
Net margin %5.921.721.014.822.220.211.611.5
EPS (₹)1.03.282.961.823.022.451.361.2

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue829687572527589495433403
Net profit1639271641761138885
Net margin %19.713.312.412.229.922.920.421.1
EPS (₹)10.245.764.454.0611.17.135.585.38

3 · The quality

How well does it turn capital into profit?

Return on equity was 27.9% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %27.916.713.412.1
Return on capital %33.626.318.016.2
EBITDA margin %32.229.225.324.0
Net margin %19.313.012.212.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR16.5%10.8%
Profit CAGR36.2%7.6%
Debt to equity0.00
Interest cover76.5x
Current ratio3.39
P/E ratio56.3

4 · The owners

Who holds it, and are they adding?

Promoter holding51.02%

Down 20.04 pts over 8 quarters.

Foreign institutions9.37%

Up 6.6 pts over 8 quarters.

Domestic institutions25.92%

Up 11.25 pts over 8 quarters.

Mutual fund schemes42

+9 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter71.0671.0671.0671.0660.9360.9260.9251.02-20.04
FII2.772.413.234.854.955.375.449.37+6.6
DII14.6714.9714.5413.4720.5120.9920.9225.92+11.25
Public11.4911.5611.1710.6313.6112.7112.7213.7+2.21

Mutual fund holdings · Oct 2026

42 schemes hold this stock

33 the month before.

  • DSP Healthcare Fund2.84% of NAV
  • NIPPON INDIA PHARMA FUND1.93% of NAV
  • ADITYA BIRLA SUN LIFE BUSINESS CYCLE FUND1.88% of NAV
  • ICICI Prudential Dividend Yield Fund1.79% of NAV
  • HSBC Midcap Fund1.54% of NAV
  • Shriram Multi Sector Rotation Fund1.52% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND1.49% of NAV
  • ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND1.43% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for THYROCARE are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about THYROCARE

What is the THYROCARE share price?

THYROCARE (THYROCARE) last closed at ₹504.85, up 0.25% on the day. Its 52-week range is ₹349.55 to ₹649.35.

What is the market cap of THYROCARE?

THYROCARE has a market capitalisation of about ₹8,013 crore. Its price-to-earnings ratio is 56.3.

How are THYROCARE's latest results?

THYROCARE reported revenue of ₹271 crore for Sep 2026, up 24.9% from a year earlier. Net profit was ₹16 crore (down 66.7% year on year). Return on equity was 27.9% in Mar 2026. Promoter holding was 51.02% in Sep 2026, down 20.04 points over 8 quarters.

Who owns THYROCARE?

As of Sep 2026, shareholding was: Promoter 51.02%, FII 9.37%, DII 25.92%, Public 13.7%.

How many mutual funds hold THYROCARE?

42 mutual fund schemes held THYROCARE in October 2026. That compares with 33 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 23 Jun 2026 · Final Dividend - Rs. 7
  • 28 Nov 2025 · Bonus issue 2:1
  • 24 Oct 2025 · Interim Dividend - Rs. 7
  • 25 Jul 2025 · Final Dividend - Rs. 21
  • 16 Aug 2024 · Final Dividend - Rs. 18
  • 20 Apr 2023 · Interim Dividend - Rs. 18

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.